Vaccinations are a hot topic as the influenza season fast approaches. Pharmacists play a vital role in the community by reducing the spread of preventable diseases through vaccine supply and administration. Pharmacist members of PDL are covered for vaccination services provided an accreditation has been obtained to administer vaccines.
Alfuria Quad®, dispensed for a patient younger than 18 years of age, was the most frequently recurring vaccine involved in incident reports to PDL in 2017. This vaccine is contraindicated for those younger than 18 years.
“Customer presented with a script for FLUQUADRI for his son who is 7 years old. I dispensed the AFLURIA QUAD brand which has the same strains of the influenza virus however is only marketed for patients 18 years or above. The vaccination was administered to the 7 year old.” – Pharmacist Report to PDL
“Script for Fluarix Tetra came in to pharmacy and dispensed as Afluria injection. Was subsequently given to an 8 year old.” – Pharmacist Report to PDL
Understandably, customers are very likely to be upset and make a formal complaint if an incident involves their child.
Beware of generic prescriptions. This can be demonstrated with the supply of Afluria Quad® where the prescription was written generically as “Influenza vaccine”. In the case of a generic prescription it is vital that the age of the patient be confirmed to avoid administering the incorrect dose.
Incident reports highlighted other vaccination issues relating to incorrect technique or incorrect site of administration. Some of these incidents led to longer term consequences for the patient and claims for lost wages and medical expenses have arisen.
It has been announced that a high dose trivalent influenza vaccine will be available through the National Immunisation Program in 2018 for people 65 years and over. Fluad® and Fluzone High Dose® are TGA-approved for patients in this age range. Currently there is no information or indication for these products in people younger than 65 years of age. If customers 65 years and over choose to pay for the convenience of vaccination in a pharmacy, they should be reminded by their pharmacist of the availability of the new high dose vaccines through the National Immunisation Program.
PDL has received several reports relating to the incorrect supply of conjugate 4vMenCV meningococcal (ACWY) vaccines. There are currently three vaccines in this group and pharmacists need to be mindful of the brand-specific guidelines based on the age of the child. Please review the product information for Menveo®, Nimenrix® and Menactra® as their administration is age-specific. The same age-based considerations apply for Japanese encephalitis vaccines JEspect® and Imojev®.
Other incidents have occured where Gardasil 9® (9vHPV) is intended though Gardasil® (4vHPV) is supplied. The 9-valent Gardisil 9® vaccine was released in 2017 and is more likely to be prescribed.
Vaccines may have a shorter shelf life compared to other products and monitoring of product expiry date is vital. Incidents relating to the supply of expired meningococcal B vaccine, Bexsero® have also occurred. This may have been due to supply difficulties. However, appropriate stock management can prevent such incidents occurring. Flag any item with a short shelf life and ensure a system is in place in your pharmacy to remove or quarantine the item once expired.
For the 2018 influenza season, the Therapeutic Goods Administration (TGA) has registered six vaccines which will be available for use in the following age groups:
Sponsor | Tradename | Age group |
Quadrivalent vaccines | ||
Sanofi-Aventis | FluQuadri Junior* | 6-35 months (<3 years) |
FluQuadri | 3 years and over | |
GlaxoSmithKline | Fluarix Tetra | 3 years and over |
Mylan Health | Influvac Tetra | 18 years and over |
Seqirus | Afluria Quad** | 18 years and over |
Trivalent vaccines | ||
Sanofi-Aventis | Fluzone High dose | 65 years and over |
Seqirus | Fluad | 65 years and over |
* Guidance for the dose in children aged 6–35 months is available in the Product Information.
** Please note that for 2018, Afluria Quad is only supplied to individuals 18 years and over. Refer to the Product Information approved in November 2017.
Product Packaging Change Win
A Practice Alert broadcast by PDL to its members in October 2017 raised awareness of the similarities in the packaging of Targin 40 and 2.5mg strengths. PDL are pleased to advise members that Mundi Pharma has recently confirmed that packaging of the Targin 2.5 is to change to differentiate it from the Targin 40.
Pharmaceutical Defence Limited (PDL) acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, waters and community. We pay our respects to the people, the cultures and the Elders past and present.